Melatonin Plus Aminoacids for Sarcopenic Elderly (MelAASarc)
Is a Combination of Melatonin and Aminoacids Useful to Sarcopenic Elderly Patients? A Randomized Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pavia, Italy, 27100
- Geriatric physical medicine and rehabilitation division at the Istituto Santa Margherita - Azienda di Servizi alla Persona di Pavia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged > or equal 65 years
- Sarcopenic patients, following the Rosetta Study criteria: Skeletal Muscle Index [SMI] was <7.23 kg/m2 in men and <5.45 kg/m2 in women) and loss of strength, evaluated by dynamometer and defined as <30 kg for men and <20 kg for women, using the average value of the two handgrip measurements of the dominant hand.
Exclusion Criteria:
- acute illnesses
- severe liver dysfunction
- severe heart dysfunction
- severe kidney dysfunction
- severe dementia
- uncontrolled diabetes
- dysthyroidism
- any endocrinopathies
- neoplasia
- patients treated with steroids
- patients entirely unable to walk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo (P)
Placebo.
|
an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
|
|
Experimental: Melatonin (M)
1 mg/day of melatonin.
|
1 mg/day 30 minutes before sleep
|
|
Experimental: Essential Aminoacids (eAA)
4 g/day of essential aminoacids
|
4g/day of Essential Aminoacids during breakfast.
Packets of powdered amino acid supplements (42.0%
leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
|
|
Experimental: Essential Aminoacids + Melatonin (eAAM)
4 g/day of essential aminoacids and 1 mg/day of melatonin
|
4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep.
Packets of powdered amino acid supplements (42.0%
leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Total Fat Mass and Total Free Fat Mass (DXA)
Time Frame: 0, 30 days
|
Body composition by dual-energy X-ray absorptiometry (DXA).
Body composition was measured by DXA, using a Lunar Prodigy DXA (GE Medical Systems, Waukesha, WI).
Free Fat mass and Fat mass of specific body regions were measured in kilograms.
|
0, 30 days
|
|
Change in Handgrip Strenght
Time Frame: 0, 30 days
|
Handgrip strength assessed using a Jamar dynamometer adhering to the standardized protocol recommended by the American Society of Hand Therapists.
A weak handgrip was defined as <30 kg for men and <20 kg for women, based on the average value of the two handgrip measurements of the dominant hand
|
0, 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Height
Time Frame: At baseline (0)
|
Height measured in meters
|
At baseline (0)
|
|
Change in Body Weight
Time Frame: 0, 30 days
|
Body Weight measured in kilograms
|
0, 30 days
|
|
Change in serum proteins
Time Frame: 0, 30 days
|
Serum proteins and albumin were measured by automatic biochemical analyzer.
They were reported as g/dl
|
0, 30 days
|
|
Change in blood lipids (total cholesterol and triglycerides)
Time Frame: 0, 30 days
|
Blood lipids (total cholesterol and triglycerides)were measured by automatic biochemical analyzer.
They were reported as mg/dl
|
0, 30 days
|
|
Change in High-sensitivity C-reactive protein (CRP)
Time Frame: 0, 30 days
|
High-sensitivity C-reactive protein (CRP) was expressed in mg/dl.
|
0, 30 days
|
|
Change in erythrocyte sedimentation rate (ESR)
Time Frame: 0, 30 days
|
Erythrocyte sedimentation rate (ESR) was expressed in mm/hr.
|
0, 30 days
|
|
Change in glycaemia
Time Frame: 0, 30 days
|
glycemia was expressed in mg/dl
|
0, 30 days
|
|
Change in Mini Nutritional Assessment (MNA)
Time Frame: 0, 30 days
|
A mini nutritional assessment (MNA) was performed for all participants.
The MNA uses 18 questions regarding simple measurements and a brief questionnaire involving an anthropometric assessment (weight, height and weight loss), a general assessment (lifestyle, medication and mobility), and a dietary assessment (number of meals, food and fluid intake, self-assessment of eating autonomy and self-perception of health and nutrition).
Every answer give up to a maximum of 3 points.
The sum of all points gives the total MNA.
A maximum of 30 points can be achieved.
A score of ≥ 24 points describes a well-nourished status.
A score of 17 to 23.5 points indicates a risk of malnutrition, while less than 17 points indicates malnutrition.
|
0, 30 days
|
|
Change in dietary intake
Time Frame: Measures taken at day 1,2,3 and at day 28,29,30
|
A trained dietitian used a calibrated dietetic spring scale to weigh all foods served and returned for 3 consecutive days at the beginning and end of the study
|
Measures taken at day 1,2,3 and at day 28,29,30
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mariangela Rondanelli, Professor, IRCCS Mondino Foundation, Pavia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Muscular Atrophy
- Atrophy
- Sarcopenia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Protective Agents
- Antioxidants
- Melatonin
Other Study ID Numbers
Other Study ID Numbers
- 1215/11122015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.